
The extent to which the PGA Tour’s legal battle with LIV Golf is about Saudi Arabia plays a starring role in new court filings.
On Nov. 22, attorneys representing the Public Investment Fund of the Kingdom of Saudi Arabia (PIF) and its governor, Yasir Othman Al-Rumayyan, moved to quash PGA Tour subpoenas that would require Al-Rumayyan to testify at depositions and to turn over sensitive documents.
The PGA Tour, PIF charges, intends to “burden” Al-Rumayyan with “unnecessary” requests as part of an effort to frame the dispute as more about the Saudi Arabian government than two golf leagues.
Related: PGA Tour Countersues LIV Golf In Escalating Antitrust Saga
Much of PIF’s argument before California federal judge Beth Lasbon Freeman is based on the Foreign Sovereign Immunities Act (FSIA). This federal law generally makes foreign governments and leaders immune from lawsuits in U.S. courts. However, under FSIA’s “commercial activity” exception, a government and leader can face trial if a lawsuit is based on their regular course of commercial conduct and if there is a sufficient connection between that conduct and the U.S.
The PGA Tour maintains that PIF effectively controls LIV Golf and thus is subject to litigation and discovery requests. But PIF insists the commercial activity exception doesn’t apply because—as PIF attorneys tell it—the two leagues’ antitrust and contract claims have “nothing to do with PIF.”
To that end, PIF works hard to distinguish LIV from PIF, which was created by royal decree in 1971 to serve the public interest and promote “economic development in the Kingdom.” PIF objects to the tour’s use of the verb “control” since, PIF asserts, the fund doesn’t control LIV’s “day-to-day operations.” PIF admits that it recently opened an office in New York City but contends “the office has a skeletal crew and leases office space … PIF has no real estate or employees in the U.S.”
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas